

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/581,580
Filing Date	March 29, 2007
First Named Inventor	Shyam S. Mohapatra
Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	USF.208TCXC1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2005/0096291 A1	05-05-2005	Iversen <i>et al.</i>	AlI
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature	/Richard Schnizer/	Date Considered	07/18/2010
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/581,580
Filing Date	March 29, 2007
First Named Inventor	Shyam S. Mohapatra
Group Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	USF.208TCXC1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AN, J. <i>et al.</i> "Development of a Novel Mouse Model for Dengue Virus Infection" <i>Virology</i> , October 1999, 263:70-77.	
	R2	BARRATT-BOYES, S. <i>et al.</i> "Maturation and Trafficking of Monocyte-Derived Dendritic Cells in Monkeys: Implications for Dendritic Cell-Based Vaccines" <i>The Journal of Immunology</i> , 2000, 164:2487-2495.	
	R3	CONDON, C. <i>et al.</i> "DNA-based immunization by <i>in vivo</i> transfection of dendritic cells" <i>Nature Medicine</i> , October 1996, 2(10):1122-1128.	
	R4	LARREGINA, A.T. <i>et al.</i> "Direct transfection and activation of human cutaneous dendritic cells" <i>Gene Therapy</i> , 2001, 8:608-617.	
	R5	PALMOWSKI, M.J. <i>et al.</i> "Intravenous Injection of a Lentiviral Vector Encoding NY-ESO-1 Induces an Effective CTL Response" <i>Journal of Immunology</i> , 2004, 172:1582-1587.	
	R6	PORGADOR, A. <i>et al.</i> "Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8 ⁺ T Cells after Gene Gun Immunization" <i>The Journal of Experimental Medicine</i> , September 21, 1998, 188(6):1075-1082.	
	R7	SONG, E. <i>et al.</i> "Antigen presentation in retroviral vector-mediated gene transfer <i>in vivo</i> " <i>Proc. Natl. Acad. Sci. USA</i> , March 1997, 94:1943-1948.	
	R8	SUBRAMANYA, S. <i>et al.</i> "Targeted Delivery of Small Interfering RNA to Human Dendritic Cells to Suppress Dengue Virus Infection and Associated Proinflammatory Cytokine Production" <i>Journal of Virology</i> , March 2010, 84(5):2490-2501.	
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature	/Richard Schnizer/	Date Considered	07/19/2010
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./